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Abstract
Soluble cervicovaginal biomarkers of inflammation, immune activation and risk of HIV
acquisition are needed to reliably assess the safety of new biomedical prevention strategies
including vaccines and microbicides. However, a fuller understanding of expression profiles
in women at high risk for HIV infection is crucial to the effective use of these potential bio-
markers in Phase 3 trial settings. We have measured 45 soluble proteins and peptides in
cervicovaginal lavage samples from 100 HIV negative women at high risk for HIV infection.
Women were followed over one menstrual cycle to investigate modulation by hormonal con-
traception, menstrual cycle phase, recent sexual exposure and intravaginal practices.
Women using injectable DMPA had increased concentration of several soluble proteins of
the innate and adaptive immune system, including IL-1α, IL-1β, IL-2, MIP-1β, IP-10, IL-8,
TGF-β, HBD4, IgA, IgG1, and IgG2. Women using combined oral contraceptives had a simi-
lar signature. There were differences in concentrations among samples from post-ovulation
compared to pre-ovulation, notably increased immunoglobulins. Increased prostate-specific
antigen, indicative of recent sexual exposure, was correlated with increased IL-6, MCP-1,
and SLPI, and decreased GM-CSF and HBD3. The identified signature profiles may prove
critical in evaluating the potential safety and impact on risk of HIV acquisition of different bio-
medical intervention strategies.
PLOS ONE | DOI:10.1371/journal.pone.0143109 January 27, 2016 1 / 28
OPEN ACCESS
Citation: Francis SC, Hou Y, Baisley K, van de
Wijgert J, Watson-Jones D, Ao TT, et al. (2016)
Immune Activation in the Female Genital Tract:
Expression Profiles of Soluble Proteins in Women at
High Risk for HIV Infection. PLoS ONE 11(1):
e0143109. doi:10.1371/journal.pone.0143109
Editor: Vikrant Sahasrabuddhe, National Cancer
Institute, UNITED STATES
Received: March 24, 2015
Accepted: October 30, 2015
Published: January 27, 2016
Copyright: This is an open access article, free of all
copyright, and may be freely reproduced, distributed,
transmitted, modified, built upon, or otherwise used
by anyone for any lawful purpose. The work is made
available under the Creative Commons CC0 public
domain dedication.
Data Availability Statement: Due to ethical
restrictions, interested researchers may submit request
for de-identified data to Saidi.Kapiga@lshtm.ac.uk.
Funding: Financial support for the Biomarkers
Project was provided by the European and
Developing Countries Clinical Trials Partnership
(project code: CT_ct_05_32070_002), the European
Combined Highly Active Retroviral Microbicides
(CHAARM-FP7 - Grant agreement n°242135 -www.
chaarm.eu), the International Partnership for
Microbicides, the Medical Research Council (MRC)
and Department for International Development
Introduction
The HIV pandemic continues to expand, with an average of 2.5 million new infections per year
[1]. The majority of these new infections are in sub-Saharan Africa, where the epidemic is
driven by heterosexual transmission and women make up 60% of the epidemic [1]. Safe, effec-
tive, female-controlled HIV prevention methods are urgently needed. Although there have
been recent successes with oral pre-exposure prophylaxis, a topical vaginal microbicide and a
parenteral vaccine [2–7], these products have been only partially protective, and the search
continues for more robust methods. Investigations following unsuccessful products in Phase 3
clinical trials, especially for products associated with increased rates of HIV infection such as
nonoxynol-9 [8], cellulose sulphate [9], and recombinant Adenovirus-5 HIV vaccines [10],
have highlighted the need to better understand immune activation in the female genital tract
for early safety assessment.
Immune activation in the female genital tract can be caused by infection, irritation or epi-
thelial trauma, and results in increased or decreased expression of soluble immune proteins
[11], and has been shown to result in attraction of cells expressing HIV co-receptors to the cer-
vicovaginal mucosa thereby increasing susceptibility to HIV infection [8]. Evidence from sev-
eral trials of ineffective or harmful microbicides has shown that some candidate products can
increase concentration of inflammatory immune proteins [8]. Increasingly, clinical studies are
measuring soluble immune biomarkers to screen for product-induced mucosal toxicity/irrita-
tion in pre-clinical and clinical trials [12–17]. The most common soluble proteins evaluated in
trials have been interleukin (IL)-1α, IL-1β, IL-1-receptor antagonist, IL-6, IL-8, tumour necro-
sis factor (TNF)-α and secretory leukocyte peptidase inhibitor (SLPI) [13–17]. Soluble immune
biomarkers may also be useful for vaccine development; not only providing safety information
for mucosal vaccines, but also for parenteral vaccines such as Adenovirus 5 that may increase
immune activation at mucosal sites [18,19].
A number of biomedical and behavioural factors can influence expression of immune pro-
teins in the female genital tract [12], and more research is needed to understand this back-
ground variation for future clinical trials. Two studies have investigated baseline variation in
low risk populations appropriate for Phase I clinical trials [20,21]; however, only one study has
investigated baseline variation among women at high risk for HIV infection in sub-Saharan
Africa [22]. There is evidence that soluble protein concentrations vary by menstrual cycle
phase [23,24], hormonal contraception use [20,25], seminal plasma exposure [26], the compo-
sition of the vaginal microbiota [22,27], and the presence of infections, including sexually
transmitted infections (STIs) [28–30]. In sub-Saharan Africa, the effect of highly prevalent vag-
inal practices, such as intravaginal cleansing, on immune proteins has only been investigated in
one study [22,31]. Lastly, many of the studies have focused on pro-inflammatory cytokines and
chemokines and, to a lesser extent, growth factors and antimicrobial proteins or peptides.
Investigating a wide array of soluble proteins in the female genital tract, including immuno-
globulins, may be useful for improving our understanding of their interactions.
To address these gaps, we measured the levels of 45 different soluble immune and antimi-
crobial proteins and peptides in cervicovaginal lavages (CVL) from 100 women participating
in an intensive longitudinal sub-study of a larger microbicide feasibility study in North-West
Tanzania. Soluble analytes evaluated included pro-inflammatory cytokines, anti-inflammatory
cytokines, growth factors, chemokines, antimicrobial proteins and immunoglobulins. We pres-
ent data from visits without known STIs, and report on the concentrations of these analytes
and the association with menstrual cycle, hormonal contraception, seminal plasma exposure,
reported intravaginal practices and clinical findings.
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Materials and Methods
Ethics Statement
All study procedures were approved by the ethics committees of the London School of Hygiene
and Tropical Medicine and the Medical Research Coordinating Committee of the Tanzanian
National Institute for Medical Research. All participants received detailed information about
the study to ensure that they understood why the study was being carried out and what the
study involved. Informed consent was obtained by signature if literate, or thumb-printed and
witnessed (if illiterate) prior to their participation in the study.
Study participants
This study was nested within a 12 month microbicide feasibility study of 970 HIV-negative
women aged 18–44 years working in bars, hotels, and other food and recreational facilities in the
three towns of Geita, Shinyanga and Kahama in northwestern Tanzania from 2008–2010. These
towns are located near large-scale gold or diamond mines in which there are large populations of
migratory male workers. This study showed a high HIV prevalence (18%) and incidence (3.7
cases per 100 woman-years) [32]. Similar populations have been targeted for recent HIV preven-
tion trials in Tanzania due to high prevalence and incidence of HIV [33,34]. The purpose of the
microbicide feasibility study was to assess feasibility, retention and appropriateness of this popu-
lation for future trials, and screening, enrolment and follow-up procedures for this cohort have
been described elsewhere [32]. We enrolled 100 women into a sub-study between August and
October 2009. Women were sampled purposefully by reported intravaginal practices at cohort
enrolment in order to ensure inclusion of women using less common intravaginal practices (e.g.
insertion with detergents). Women who were HIV positive, pregnant, currently breastfeeding, or
had previous known cervical or uterine abnormalities or surgery (“Have you ever been told that
you have a problem with your cervix or uterus?” and “Have you ever had an operation on your
cervix or uterus?”) were excluded from the study. Women who were menstruating during the
enrolment visits were asked to return after the completion of menses.
Study design
Participants enrolled in the sub-study were followed up three times a week for 4 weeks (12 visits
total). At enrolment, interviews were carried out to obtain information about sexual behaviour,
vaginal practices, current contraception, and STI symptoms. On the first and last visit (visits 1 &
12), a clinical and colposcopic examination were performed; cervical and vaginal swabs were col-
lected to test for vaginal pH and reproductive tract infections (Chlamydia trachomatis, Neisseria
gonorrhoeae, Trichomonas vaginalis, bacterial vaginosis, and yeast); and a CVL was obtained for
the detection ofHerpes simplex virus, types 1 and 2 (HSV), prostate-specific antigen (PSA) to
measure seminal plasma exposure in the last 48 hours [35], soluble immune proteins, haemoglo-
bin and white blood cells (WBCs). During visits 2 to 11, a shortened interview was conducted to
obtain updated sexual behaviours and intravaginal practices. A brief clinical examination was per-
formed to obtain vaginal swabs for testing vaginal pH, bacterial vaginosis and yeast, and a CVL
for the detection of HSV, PSA, soluble immune proteins, haemoglobin andWBCs. Urine was col-
lected at every visit to test for pregnancy andmenstrual cycle phase. If a woman was menstruat-
ing, no genital samples were obtained on that visit. No blood samples were collected; however
laboratory data from the main cohort on HSV antibody status, HIV status and syphilis results
were available for the statistical analysis and methods have been reported in a previous study
[32]. Colposcopy was carried out by trained clinicians according to the CONRAD/WHO revised
manual for the Standardization of Colposcopy for the Evaluation of Vaginal Products [36].
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Sample processing and laboratory testing
CVL sample processing. CVL samples were obtained by flushing 5ml of sterile normal
saline with a sterile pipette over the cervix and the lateral vaginal walls. After 60 seconds, the
fluid was aspirated from the posterior fornix using the same pipette and collected in a 15 ml
conical polypropylene tube that was then stored temporarily in a cool box with ice (2–8°C)
before processing. Visual appearance was noted and documented, and 10μl of samples was
used to assess the sample for haemoglobin using Hemastix1 reagent indicator strips (Bayer
Diagnostics, Tarrytown, NY, USA), comparing the indicator colouring with colour categories
representing approximate quantities of erythrocytes (ery) per uL as specified by the manufac-
turer: none, low (25 ery/μL), moderate (80 ery/μL), high (200 ery/μL). CVLs were centrifuged
onsite at 3500 rpm for 10 minutes within two hours of collection. Protease inhibitor (Cocktail
Set I, Calbiochem, Merck Millipore, Darmstadt, Germany) was added to two 1 ml aliquots for
immune protein testing, and two 1ml aliquots were stored for batch testing for PSA and HSV
viral quantification. CVL supernatant aliquots were stored at -20C° for 3 days and then at
-80°C for long-term storage before shipping or batch testing.
We developed a method to enumerate the WBCs in the cell pellet modified from a manual
blood count: the cell pellet was spread across a glass slide, fixed with methanol and air-dried.
Leishman’s stain was applied to the slide for 10 minutes. With a light microscope at 100 times
magnification, WBCs were counted and recorded on a differential cell counter until 100 WBCs
were counted. Erythrocytes and epithelial cells were enumerated on a separate counter, and
were not included in the 100-cell differential count.
Measurement of vaginal pH and reproductive tract infections. At the first and last visit,
an endocervical swab was tested for detection of N. gonorrhoeae and C. trachomatis by Ampli-
cor PCR kits (Roche Diagnostics, Branchburg, USA). All positive tests for N. gonorrhoeae were
confirmed using specific primers to the 16S DNA coding region in PCR in-house assays [37].
A vaginal swab was obtained to inoculate a culture (TV InPouch, Biomed Diagnostics, San
Jose, USA), which was read for the presence of motile trichomonads by light microscopy at 72
hours after incubation at 36–37°C.
At each visit, CVL supernatants were tested for HSV shedding using Artus HSV-1/2 PCR
kits (Qiagen, Hilden, Germany). A vaginal swab was Gram-stained and examined and Nugent
scored for diagnosis of bacterial vaginosis [38]. A third swab was rolled onto a pH indicator
strip (ThermoFisher, Waltham, MA, USA); the indicator colouring was compared with colour
zones representing the following pH values: 3.6; 4.1; 4.4; 4.7; 5.0; 5.3; 5.6 and 6.1. The same
swab was used for wet mount microscopy for the detection of yeast hyphae or buds.
Measurement of PSA. Wemeasured PSA at every visit using a quantitative PSA ELISA
Kit (Calbiotech, Inc, Spring Valley, CA, USA) for the detection of PSA in human serum for
cancer detection. A random selection of CVL supernatant aliquots were shipped to the Institute
of Tropical Medicine in Antwerp, Belgium for evaluation against the SERATEC PSA Semi-
quant (Göttingen, Germany). The SERATEC test is a semi-quantitative chromatographic
immunoassay also originally developed for human serum for cancer detection, and subse-
quently validated for the detection of PSA in vaginal fluid for professional forensic purposes
with a sensitivity and specificity of 100% [39]. The Calbiotech test was found to be 70% sensi-
tive and 100% specific for PSA in the cervical vaginal lavages against SERATEC when combin-
ing low positive (<4ng/ml) and negative values.
Measurement of immune proteins and peptides. Twenty-three soluble immune protein
were quantified by in house multiplex bead immunoassay as previously described (Panels a
and b of Figure A in S1 Fig) [40,41]. Following the same protocols, two more panels were
added to measure human beta defensins(HBD)3, apolipoprotein(APO)A1, squamous cell
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carcinoma antigen(SCCA)-1, polymeric immunoglobulin receptor (PIGR), IL-10, IL-17, IL-18
and transforming growth factor(TGF)-α (Panel c of Figure A in S1 Fig) and SLPI, elafin,
HBD2, HBD3, α-defensin/human neutrophil peptide (HNP) 1–3, involucrin and S100 calcium
binding protein A8 (S100a8) (Panel e of Figure A in S1 Fig). Additionally, six immunoglobulin
(Ig) isotypes (IgG1, IgG2, IgG3, IgG4, IgA, IgM) were measured using Milliplex map kit
(Merck Millipore, Billerica, USA; Cat No: HGAM-301) following the manufacturer’s protocol
(Panel d of Figure A in S1 Fig). Total protein was measured using Quick Start™ Bradford Pro-
tein Assay (Bio-Rad Laboratories, Hercules, USA).
Measurement of menstrual cycle phase. Urine aliquots were stored at -80°C for testing
for Pregnanediol-3-Glucuronide (PDG, EIA, Immunometrics UK Ltd, London, United King-
dom), the principal metabolite of progesterone, and for testing of creatinine (CRT, R&D Sys-
tems, Inc., Minneapolis, MN, USA). Each PDG concentration was indexed by the CRT
concentration of the same sample to adjust for urine dilution. We used a modified Kassam
method to identify ovulatory cycles during the study; we used the minimum PDG/CRT value
for each women during the study as the denominator, and the per-visit PDG/CRT value as the
numerator [42]. A ratio threshold of greater than 4.0 signalled that ovulation had taken place
[42,43]. This method has been used for twice weekly and every other day sampling, and found
to be 100% sensitive and 77% specific with 6% misclassification [43]. In those women who
reported no hormonal contraceptive use, who showed evidence of ovulation, and who had one
observed menstruation, we then examined the PDG curves to identify the rise in PDG. We
defined “Day 1” of the menstrual cycle as the first visit with observed menstruation. All visits
after Day 1 were defined as pre-ovulation until a rise in PDG was seen, and all subsequent visits
were defined as post-ovulation until menstruation. If there was no obvious PDG rise, visits
were not categorized for analysis.
Statistical analysis
Data were analyzed using Stata, version 12 (StataCorp, College Station, USA). We restricted
the data set to “healthy visits” defined as visits without a positive STI test or reproductive tract
infection. Visits were excluded from this analysis if results were positive for HSV shedding,
vaginal yeast or bacterial vaginosis. In addition, all follow-up visits for women who tested posi-
tive at the first or last visit for C. trachomatis, N. gonorrhoeae, and T. vaginalis were excluded
from this analysis.
CVL samples with analyte concentrations below the lower limit of quantification (LLOQ) of
the assay were assigned a concentration of half the LLOQ. Those above the upper limit of
quantification (ULOQ) were assigned values twice the ULOQ. Spearman’s rank correlation
coefficient was calculated for each of the analytes within a Luminex panel to look for evidence
of cross-reactivity (Figure A in S1 Fig).
The proportion of samples with concentration above the LLOQ, and the median and range
of concentrations above the LLOQ, were calculated for each analyte. Since most analytes
showed skewed distribution, concentrations were log10 transformed. To characterize the varia-
tion of the analytes over time between and within women, we used mixed-effects linear regres-
sion to estimate the ICC of each log-transformed value; variance components were estimated
using residual maximum likelihood. The ICC was calculated as σB
2/ (σB
2 + σW
2), where σB
2 is
the between-women variance and σW
2 is the within-woman variance. An ICC of 0 implies that
observations from the same woman are no more similar to each other than they are to observa-
tions from different women. An ICC of 1 implies that all observations from the same woman
are identical, so that the variation is due to between-woman differences. We also explored the
effects of the dilution factor of the CVL by ICC (Table A in S1 Table and S1 Text).
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We examined the association of analytes concentrations with the following exposures: men-
strual cycle stage, hormonal contraception (reported use of combined oral contraceptive
[COC] or injectable depot medroxyprogesterone acetate [DMPA]), seminal plasma, reported
vaginal practices, cervical ectopy, colposcopic findings, and vaginal pH. Since detailed clinical
examinations were only done at Visits 1 and 12, ectopy and colposcopy results were not avail-
able at other time points. To explore the association with the exposures of interest, we used
mixed-effect linear regression for analytes with concentration>85% above LLOQ, or logistic
regression with random effects for analytes with concentration85% above LLOQ.
For the analysis, PSA was categorised into three levels: no PSA detected; low positive
(<4ng/ml); and high positive (4ng/ml). Neutrophil counts were categorised into the follow-
ing levels per 100 WBCs: no cells, 1–10 cells, 11–50 cells,>50 cells, and lymphocytes were
analysed as presence/ absence. Vaginal pH results were categorised into the following levels:
3.6–4.1 (normal pH); 4.4–4.7 (high normal pH); and 5.0 and above (abnormal pH).
For each of the analyses of intravaginal cleansing with soap, intravaginal cleansing with
cloth, and intravaginal insertion (i.e. the insertion of pulverized herbs or detergents), we com-
pared samples from visits in which women reported the specific intravaginal practice to visits
in which no cleansing or cleansing with fingers and water only was reported. We excluded vis-
its in which women reported insertion of prescribed medications (e.g. treatment for candidia-
sis), leaving all but two women inserting detergents.
In the multivariable analysis, we considered age, reported sex in the past 3 days, and the
presence of haemoglobin in the CVL as a priori confounders based on a conceptual model
(Figure B in S1 Fig). For menstrual cycle phase, hormonal contraceptive use, intravaginal prac-
tices, clinical cervical ectopy, colposcopic abnormalities, and vaginal pH we controlled for the
effects of age, reported sexual intercourse in the past three days and presence of haemoglobin;
for PSA we controlled for age and presence of haemoglobin.
Results
Demographics, behavioural characteristics and clinical findings of the
participants
One hundred participants attended 1,108 (92%) of 1,200 possible visits over follow-up. Of the
1,108 visits, 956 (86%) were non-menstruating, and of these, 370 (39%) met the definition of
healthy visits; 67 women contributed at least one visit to this analysis. The participant demo-
graphic, behavioural, contraception and menstrual cycle data, and clinical and laboratory find-
ings by visit are presented in Table 1. The mean age was 26 years old (range 18–44 years).
Approximately one-quarter (28%) reported current use of hormonal contraception (i.e. COC
or DMPA) at enrolment, 81% reported sexual intercourse during the study period, and 100%
reported practicing vaginal cleansing during the study period. For cleansing, 81% used soap,
21% used a cloth (versus fingers alone), and 39% reported insertion of a substance into the
vagina (e.g. herbs) at least once during the study.
There was evidence of ectopy at 28 of 71 (39%) possible healthy visits; the majority of cases
of ectopy involved less than 20% of the cervix face. Colposcopy findings were detected at 21%
(16/71) of visits: 15 cases were cervical findings (13 petechiae, 1 erythema and 1 ecchymosis);
and one was on the anterior fornix (petechiae). There were no findings of oedema, grossly
white findings, peeling, ulcer, abrasion or laceration.
In over half of the visits (58%), the vaginal pH was between 4.7 and 5.0, with only 14% of
visits having a pH>5.0. Overall, 49% tested positive for PSA. Two-thirds of the samples (67%)
tested positive for haemoglobin; 20% of samples with detectable haemoglobin were at visits
flanking an observed menstrual period. However, of the 65 samples with high haemoglobin
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Table 1. Demographics, behaviour and clinical characteristics.
Demographic and behavioural characteristics (N = 67) N(%)
Age (Mean, range) 26 (18–44)
Reported vaginal intercourse during the study 54 (81%)
Reported intravaginal cleansing during the study
Any cleansing 67 (100%)
Use of soap1 54 (81%)
Use of cloth 14 (21%)
Reported intravaginal insertion during the study
Any insertion 26 (39%)
Medication 6 (9%)
Detergent1 18 (27%)
Herbs 1 (2%)
Tobacco 1 (2%)
Contraception at enrolment (N = 67)
No contraception 19 (28%)
Condom use only 23 (34%)
Depot medroxyprogesterone acetate (DMPA) 13 (19%)
Combined oral contraceptive (COC) 6 (9%)
Sterilization 3 (5%)
IUD 1 (2%)
Other 2 (3%)
Menstrual cycle
The number of cycles that could be assigned as ovulatory2 (n = 48) 46 (96%)
The number of menstruations during the study per participant3 (n = 46)
No menstruation observed 11 (24%)
One menstruation 33 (72%)
Two menstruations 2 (4%)
Visits that could be assigned a menstrual cycle phase4 (n = 102 visits)
Pre-ovulation 56 (55%)
Post-ovulation 46 (45%)
Clinical and laboratory ﬁndings by visit (N = 370)
Cervical ectopy at V1 & V12 (n = 71 visits)
Absent 43 (61%)
<20% 27 (38%)
20% 1 (1%)
Colposcopic ﬁndings5 at V1 & V12 (n = 71 visits)
Absent 55 (78%)
Vaginal 0 (0%)
Fornices 1 (0.01%)
Cervical 15 (21%)
Vaginal pH measured at each visit6 (V1-V12; n = 361 visits)
3.6–4.1 66 (19%)
4.4–4.7 145 (40%)
5.0 + 150 (72%)
Prostate speciﬁc antigen (PSA) measured at each visit (V1-V12; n = 370 visits)
Negative 189 (51%)
Low positive (<4ng/ml) 118 (32%)
High positive (4ng/ml) 63 (17%)
(Continued)
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(200 ery/uL), only 46% were at the visit before and after an observed menstrual period. Thus,
menstrual blood may have accounted for some, but not all of the haemoglobin found in the
samples. WBCs were found in 51% of the CVL cell pellets, and these were mostly neutrophils
with a lower proportion of lymphocytes.
In the 48 women who did not report hormonal contraception use, 46 (96%) showed signs of
having ovulatory cycles; however, of these, 11 (24%) did not have an observed menstruation
during the study period, and two had two separate menstruations. In the 33 women who
showed evidence of ovulation and had one observed menstruation, 102 of 169 (63%) visits
could be assigned as either pre-ovulatory or post-ovulatory.
Expression patterns for soluble immune proteins in cervicovaginal
lavages (CVLs)
Distributions of the analyte concentrations are visualized in Fig 1. Most analytes were detect-
able by the assays that were used, with only 13 out of 38 analytes having concentrations below
LLOQ in15% of visits at which they were measured (Table 2). For the comparison of bio-
medical and behavioural factors, these analytes were analysed as binary variables (i.e. presence/
absence). Details of the median, range, mean and standard deviation, as well as percentages
detected for each analyte from healthy visits are given in Table 2.
Inter- and intra-woman variation in analyte concentration differed from one analyte to
another (Table 2). For all analytes, there was strong evidence of a correlation between repeated
samples within the same woman over time (p<0.001). For most analytes, the ICC was close to
0.50 (median = 0.45, IQR = 0.38–0.51).
Menstrual cycle phase signature. Compared to samples from visits during pre-ovulation,
samples from visits during post-ovulation had increases in IL-18, IL-10, IL-17, and TGF-β, and
a decrease in monocyte chemotactic protein (MCP)-1, stromal cell-derived factor (SDF)-1β,
Table 1. (Continued)
Demographic and behavioural characteristics (N = 67) N(%)
Haemoglobin presence in CVL measured at each visit7 (V1-V12; n = 369 visits)
Negative 123 (33%)
25 Ery/uL (+) 121 (33%)
80 Ery/uL (++) 60 (16%)
200 Ery/uL (+++) 65 (18%)
1. Soaps were deﬁned as soaps meant for cleansing the body, while detergents were for cleaning clothes,
dishes, etc.
2. We used a modiﬁed Kassam method to identify ovulatory cycles during the study; we used the minimum
pregnanediol 3-glucuronide/ creatinine (PDG/CRT) value for each women during the study as the
denominator, and the per-visit PDG/CRT value as the numerator. A ratio threshold of greater than 4.0
signalled that ovulation had taken place [51,52].
3. In those women who reported no hormonal contraceptive use and showed evidence of ovulation.
4. In those women who reported no hormonal contraceptive use, showed evidence of ovulation, and with
one observed menstruation, pre and post ovulation was deﬁned by the rise in pregnanediol 3-glucuronide.
5. The colposcopic ﬁndings on the fornix were petechiae (1 case), and on the cervix were petechiae (13
cases) erythema (1 case) and ecchymosis (1 case). There were no ﬁndings of oedema, grossly white
ﬁndings, peeling, ulcer, abrasion or laceration.
6. Vaginal pH was measured using ThermoFisher pH test strips (range 3.6–6.1) with a colour chart.
7. Haemoglobin was measured using Hemastix1 test strips with a colour chart.
doi:10.1371/journal.pone.0143109.t001
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Fig 1. Distribution of analyte concentrations in cervicovaginal lavage samples for 370 healthy visits.
Each data point represents a single sample and the line through data points represents the median
concentration. APOA1 and albumin are serum controls and SCCA-1 and involucrin are vaginal epithelial
controls.
doi:10.1371/journal.pone.0143109.g001
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Table 2. The proportion of samples with analytes detected, median, mean and intra–class correlation coefficients (ICC) from 370 CVL samples.
Analyte Percent with concentrations
above LLOQ1
Median (range) CVL
concentration
Mean (standard deviation)
CVL concentration
σ; ICC; σw of log–transformed
data2 (N = 302)3,4
Inﬂammatory cytokines pg/ml pg/ml
IL–1α /IL–1F1 100% 24.7 (1.5–7093.6) 83.4 (401.1) 0.35; 0.51; 0.35
IL–1β /IL–1F2 93% 17.0 (0.5–19069.8) 204.5 (1330.4) 0.58; 0.52; 0.55
IL–6 95% 14.2 (0.7–3049.1) 68.0 (234.2) 0.50; 0.48; 0.53
IL–125 77% 11.5 (0.1–356.1) 16.2 (26.7) 0.46; 0.55; 0.42
IL–18 (n = 301) 92% 21960.0 (125.0–
1055770.0)
49244.1 (100235.8) 0.54; 0.46; 0.58
TNF-α5 41% 1.0 (0.2–75.2) 3.9 (9.8) 0.36; 0.52; 0.35
Anti-inﬂammatory cytokines pg/ml pg/ml
IL–10 (n = 301) 86% 55.3 (3.5–660.5) 78.1 (78.3) 0.34; 0.43; 0.39
Adaptive cytokines pg/ml pg/ml
IFN-y5 36% 7.1 (0.1–140.0) 12.7 (19.3) 0.31; 0.42; 0.37
IL–2 93% 24.8 (2.1–342.0) 30.5 (25.8) 0.30; 0.55; 0.27
IL–45 49% 2.8 (0.3–20.9) 3.6 (3.1) 0.25; 0.40; 0.31
IL–155 44% 0.8 (0.1–7.8) 1.1 (1.2) 0.33; 0.57; 0.29
IL–165 69% 67.5 (3.7–1931.3) 128.2 (238.4) 0.36; 0.50; 0.36
IL–175 (N = 301) 82% 32.7 (1.0–1203.1) 87.9 (162.9) 0.45; 0.49; 0.46
CC Chemokines pg/ml pg/ml
MIP–1α5/CCL3 60% 7.8 (0.6–49.3) 10.1 (7.8) 0.27; 0.41; 0.33
MIP–1β/CCL4 89% 23.1 (0.5–760.6) 46.1 (83.5) 0.30; 0.41; 0.37
MCP–1/CCL2 88% 14.8 (1.8–6034.7) 75.4 (368.0) 0.38; 0.31; 0.57
MCP–25/CCL8 63% 8.4 (0.2–74.0) 9.8 (8.5) 0.33; 0.44; 0.38
RANTES/ CCL5 86% 4.0 (0.2–555.2) 17.5 (56.8) 0.52; 0.54; 0.48
CXC Chemokines pg/ml pg/ml
IP–10/ CXCL10 99% 287.5 (7.4–4686.0) 574.8 (768.2) 0.42; 0.52; 0.41
SDF–1β/
CXCL125
41% 71.7 (17.4–2071.5) 163.0 (295.9) 0.30; 0.51; 0.30
MIG/CXCL95 75% 5354.9 (174.2–115344.4) 9778.1 (14319.5) 0.58; 0.61; 0.46
IL–8 100% 491.1 (4.6–82557.8) 1317.0 (4957.9) 0.37; 0.46; 0.40
Growth Factors pg/ml pg/ml
GM–CSF 95% 4.4 (0.2–84.9) 5.9 (6.2) 0.31; 0.49; 0.32
G–CSF 92% 30.4 (2.2–225.6) 261.1 (476.0) 0.50; 0.55; 0.45
TGF–α 89% 40.1 (0.4–322.9) 36.8 (28.2) 0.33; 0.57; 0.28
TGF–β 99% 104.3 (0.8–4507.0) 54.5 (47.5) 0.34; 0.37; 0.45
Antimicrobial proteins ng/ml ng/ml
IFN–β5 64% 0.3 (0.0–8.6) 0.4 (0.8) 0.42; 0.42; 0.50
SLPI 100% 238.5 (5.0–10892.2) 441.8 (869.3) 0.28; 0.33; 0.40
Elaﬁn 100% 107.0 (9.6–7548.3) 185.7 (459.0) 0.22; 0.41; 0.26
s100a8 (n = 302) 100% 9.9 (1.1–159.7) 13.9 (15.8) 0.21; 0.37; 0.27
HNP 1–3 100% 342.9 (4.0–28582.2) 1635.1 (3703.9) 0.45; 0.38; 0.57
HBD2 (n = 302) 95% 446.2 (0.3–17689.2) 1374.6 (2435.7) 0.49; 0.38; 0.62
HBD3 (n = 301) 97% 7.8 (0.1–2807.2) 132.8 (410.9) 0.57; 0.32; 0.83
HBD4 (n = 302) 86% 0.4 (0.0–3.2) 0.5 (0.5) 0.32; 0.49; 0.33
Immunoglobulins ng/ml ng/ml
pIgR (n = 301) 99% 68.9 (0.3–2198.1) 144.2 (250.5) 0.41; 0.42; 0.49
IgA (n = 230) 96% 401.1 (30.3–14977.4) 1016.9 (2024.7) 0.37; 0.36; 0.50
IgM5 (n = 230) 75% 137.6 (6.6–17905.0) 562.0 (1594.1) 0.51; 0.44; 0.57
(Continued)
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IgA, IgG2 and IgM (n = 102; Fig 2; Table B in S1 Table). There were no detectable difference in
expression of antimicrobial proteins with menstrual cycle phase.
Hormonal contraception signatures. Compared to women who reported no hormonal
contraceptive use, women reporting DMPA use had an increase in concentration of several sol-
uble proteins of the innate and adaptive immune system, including IL-1α, IL-1β, IL-6, TNF-α,
IL-2, IL-4, IL-16, interferon (IFN)-γ, macrophage inflammatory protein (MIP)-1α, MIP-1β,
MCP-2, IP-10, SDF-β, monokine induced by gamma interferon (MIG), IL-8, TGF-β, IFN-β,
HBD4, IgA, IgG1, and IgG2 (n = 327; Fig 3A and 3B; Table B in S1 Table). Women reporting
COC use had a similar signature with increases in IL-1β, IL-2, IL-6, IL-8, MIP-1β, MCP-2,
G-CSF, HNP 1–3, HBD4, and SCCA-1 (n = 305; Fig 3C and 3D; Table B in S1 Table).
Signature for the detection of prostate-specific antigen. There was modest evidence of a
positive linear correlation between PSA levels and IL-6, MCP-1, SLPI, APOA1, and evidence of
a negative linear correlation with s100a8, GM-CSF, and HBD3 (n = 370; Fig 4; Table B in S1
Table).
Intravaginal practice signatures. For the analysis of cleansing with soap, the analyte sig-
nature showed no evidence of a difference between women who used soap versus no cleansing
or cleansing with water alone (Table B in S1 Table). For the analysis of cleansing with cloth,
there was evidence of an increase in the innate and adaptive immune system proteins, includ-
ing IL-1β, IL-2, IL-8, MIP-1β, SDF-1β, RANTES, IP-10, HNP 1–3, HBD4, IFN-β, and immu-
noglobulins (n = 155; Fig 5A and 5B; Table B in S1 Table). For the analysis of insertion, with
exception of IL- β, TNF-α and IFN-γ, most of the other analytes trend towards a decrease for
visits with reported insertion (n = 145; Fig 5C and 5D; Table B in S1 Table).
Analyte signatures from clinical findings. For the analysis of cervical ectopy, we com-
pared samples from women who had any ectopy at the first and last visit to samples from
Table 2. (Continued)
Analyte Percent with concentrations
above LLOQ1
Median (range) CVL
concentration
Mean (standard deviation)
CVL concentration
σ; ICC; σw of log–transformed
data2 (N = 302)3,4
IgG1 (n = 230) 99% 9123.7 (355.3–110238.7) 14815.8 (17047.5) 0.23; 0.14; 0.57
IgG2 (n = 230) 90% 3963.0 (325.8–96848.8) 7478.8 (10841.0) 0.41; 0.48; 0.43
IgG3 (n = 230) 97% 312.3 (18.6–18261.1) 666.5 (1466.2) 0.33; 0.20; 0.67
IgG4 (n = 230) 90% 80.7 (0.9–2662.5) 250.7 (422.5) 0.71; 0.68; 0.48
Controls ng/ml ng/ml
APOA1 (n = 302) 100% 0.04 (0.0–78.6) 1.3 (6.0) 0.65; 0.36; 0.86
SCCA–1
(n = 301)
97% 122.7 (0.5–5072.3) 254.2 (503.8) 0.36; 0.31; 0.55
Albumin
(n = 302)
100% 1802.4 (27.7–284126.9) 5761.3 (20514.8) 0.38; 0.46; 0.42
Involucrin
(n = 302)
100% 50.1 (0.7–33668.8) 431.9 (2351.2) 0.47; 0.46; 0.51
Total protein 100% 123290.0 (27517.2–
786809.2)
148872.1 (104461.5) 0.19; 0.42; 0.22
1. Samples with analyte concentrations below the lower limit of quantiﬁcation (LLOQ) of the assay were assigned a concentration of half the LLOQ.
2. σ = variance between women; ICC = intra-class correlation coefﬁcient; σw = within-woman variance.
3. Restricted to 302 samples in which involucrin was measured.
4. For all of the analytes, there is strong evidence of clustering within women—i.e. strong evidence that ICC >0; the p-value is <0.001 calculated by
ANOVA, using an F test of between-women variation/within-women variation.
5. Biomarkers with <85% observations below the limit of quantiﬁcation
doi:10.1371/journal.pone.0143109.t002
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Fig 2. Menstrual cycle phase (n = 102). A comparison of analyte concentration between samples from visits
occurring post-ovulation to pre-ovulation (reference). Menstrual cycle stage was assessed by measurement
of urine pregnanediol 3-glucuronide. Bolded analytes represent associations with a p-value0.05. (A)
Analytes with85% detection using linear regression showing coefficients (boxes) and confidence intervals
(lines) (B) Analytes with <85% detection using logistic regression showing odds ratios (boxes) and
confidence intervals (lines).
doi:10.1371/journal.pone.0143109.g002
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Fig 3. Reported hormonal contraceptive use (DMPA, n = 327; and COC, n = 305). Bolded analytes
represent associations with a p-value0.05. (A) A comparison of analyte concentration85% between
samples DMPA and women who reported no hormonal contraception use (reference) using linear regression.
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women who had no clinical ectopy. Samples from visits with clinical ectopy showed some evi-
dence of an increase in IL-6 and G-CSF (n = 67; Fig 6; Table B in S1 Table).
For the analysis of colposcopy, we compared samples from women who had any colpo-
scopic finding (88% [14/16] were petechiae) at the first and last visit to samples from women
who had no colposcopic findings. Samples from visits with colposcopic findings showed a
decrease in IL-2, RANTES, and GM-CSF compared to visits without colposcopic findings
(n = 67; Fig 7; Table B in S1 Table).
There was some evidence for a negative linear correlation between pH and the concentra-
tion of inflammatory cytokine IL-18; adaptive cytokine IL-2; growth factors GM-CSF and
TGF-β; and HBD3 (n = 361; Fig 8; Table B in S1 Table). There was evidence of a positive linear
correlation of pH with IgA, IgG4 and APOA1.
Signatures fromWBCs identified in the CVL cell pellet. We carried out analyses for
neutrophils and lymphocytes only because there were too few other WBCs reported. There was
evidence for strong positive linear correlation between neutrophil count and the concentration
of analytes in the innate and adaptive immune system, including IL-1α, IL-1β, IL-6, MIP-1β,
IP-10, IL-8, G-CSF, TGF-α, HNP 1–3, HBD2, HBD4, immunoglobulins, APOA1, albumin,
and total protein (n = 361; Fig 9; Table B in S1 Table). For the analysis of lymphocytes, we com-
pared samples that had any lymphocytes to those that had none. There was strong evidence of
a positive association between samples that had detectable lymphocytes and IL-1β, IL-6,
RANTES, G-CSF, IgG2, and APOA1, albumin and total protein, and a negative association
between samples with detectable lymphocytes and IgG1 (n = 361; Fig 9; Table B in S1 Table).
Signatures from samples with haemoglobin. There was evidence for strong positive lin-
ear correlation between haemoglobin category and concentration of IL-1β, IL-6, IL-10, MIP-
1β, MCP-1, RANTES, IP-10, IL-8, G-CSF, TGF-α, immunoglobulins, APOA1, albumin and
total protein (n = 369; Fig 10; Table B in S1 Table).
Adjustments for age, recent sex and samples with haemoglobin. We controlled for the
effects of age, reported sexual intercourse in the past three days and presence of haemoglobin.
All signatures showed little change after adjustment (Figs C-K in S1 Fig). Adjusted coefficients
can been found in Table C in S1 Table.
Discussion
Wemeasured 45 different soluble immune proteins and peptides in CVLs from women taking
part in a microbicide feasibility study, and who would be appropriate for enrolment into Phase
3 clinical trials for HIV prevention candidate products. During healthy visits, we found differ-
ential expression of soluble immune proteins by hormonal contraception use, menstrual cycle
stage, recent sexual exposure, clinical findings, and some types of traditional intravaginal prac-
tices. Increasingly, inflammatory cytokines and other soluble immune proteins are being used
to assess the potential safety of candidate microbicides, vaccines or other HIV prevention
(B) A comparison of analyte concentration <85% between samples from women who reported use of DMPA
and women who reported no hormonal contraception use (reference) using logistic regression. (C) A
comparison of analyte concentration85% between samples from women who reported use of COC and
women who reported no hormonal contraception use (reference) using linear regression. (D) A comparison of
analyte concentration <85% between samples from women who reported use of COC and women who
reported no hormonal contraception use (reference) using logistic regression. Footnotes: 1. The x-axis range
is from -1 to +2 which is wider than for all other figures; 2. For the association with DMPA and IL-12, odds
ratios could not be estimated as all DMPA visits had detectable IL-12 levels; 3. For the association with COC
use and IgM, odds ratios could not be estimated as all COC visits had detectable IgM levels.
doi:10.1371/journal.pone.0143109.g003
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Fig 4. Prostate-specific antigen (PSA, n = 370). PSA categories: None, low positive (<4 ng/mL), high
positive (4 ng/mL). Bolded analytes represent associations with a p-value0.05. (A) Analytes with85%
detection using linear regression, linear trend for change in log concentration. (B) Analytes with <85%
detection using logistic regression, change in odds of analyte detection (if <85% LLOQ) with one unit
increase in exposure category.
doi:10.1371/journal.pone.0143109.g004
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Fig 5. Traditional intravaginal practices (intravaginal cleansing with cloth, n = 155; and intravaginal
insertion, n = 145). Bolded analytes represent associations with a p-value0.05. (A) A comparison of
analyte concentration85% between samples from women who reported intravaginal cleansing with cloth
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products [12,13]. These behavioural and biological factors should be taken into account in the
design, analysis and interpretation of clinical trials using these analytes.
DMPA and COCs are the most popular forms of contraception in East and southern Africa
[44]. A recent meta-analysis has suggested that DMPA, but not COCs, increase risk for HIV
acquisition [45]. Our study showed an increase in innate and adaptive, inflammatory and anti-
inflammatory analytes, signalling an overall heightened inflammatory state among women
using DMPA and a similar signature for women using COCs. This is consistent with two recent
studies showing increases in cytokines and chemokines among women using DMPA [46,47]
and COCs [46]. Both studies suggest that the reported increase in RANTES among DMPA
users may be a key factor underlying epidemiological associations between DMPA use and
increased HIV acquisition; while COCs users showed no evidence of an increase in RANTES
[46]. In our study, we see a trend towards an increase in RANTES among DMPA users; how-
ever, confidence intervals are wide. More studies are needed to investigate safety of effective
contraception among women at high risk for HIV infection.
In contrast to hormonal contraception signatures, menstrual cycle phase signatures had rel-
atively less differential expression. Consistent with our findings, both human and macaque
studies have shown that IgA and IgM levels in the cervical mucus are decreased during the
post-ovulation phase [48,49]. Published literature report differential expression of other soluble
immune proteins by menstrual cycle phase [50], but the evidence is less consistent in in vivo
studies. For example, concentrations of IL-1β and IL-6 have been found to be lower post-ovula-
tion in one study of HIV-negative, pre-menopausal women in the US [24], but in a study
among women living with HIV infection, levels of IL-1β and IL-6 were similar during pre-ovu-
lation and post-ovulation phases [23]. In a study of healthy Belgian women, levels of IL-1β and
IL-6 were also similar during pre-ovulation and post-ovulation phases, but there were increases
in IL-1α and HBD1-3 post-ovulation. Additionally, in a small study that obtained vaginal biop-
sies from women pre-ovulation and post-ovulation, there were no differences in immune cell
populations [51].
We measured PSA as a biomarker of recent seminal plasma exposure and found some evi-
dence of differential expression with increasing PSA. A study of healthy Belgian women also
reported a strong correlation between PSA and IL-6 [21]. Seminal plasma has been reported to
stimulate pro-inflammatory cytokines and chemokines such as IL-8, IL-6, MCP-1 and
GM-CSF in immortalized cervical cells, as well as stimulate infiltration of the cervix by macro-
phages, dendritic cells, and T lymphocytes [26]. It is thought that inflammation may facilitate
preparation of the female reproductive tissues for pregnancy through clearance of pathogens,
sperm selection, and induction of immune tolerance toward the semi-allogeneic embryo [52].
Additionally, epithelial microabrasions from sexual intercourse may cause immune activation;
a small study reported that microabrasions were detected in 60% of healthy women after con-
sensual intercourse [53].
Cervical ectopy typically occurs during times of increased oestrogen levels, including adoles-
cence, pregnancy and among women taking oestrogen-containing hormonal contraceptives.
and women who reported no intravaginal cleansing use or intravaginal cleansing with water alone (reference)
using linear regression. (B) A comparison of analyte concentration <85% between samples from women who
reported intravaginal cleansing with cloth and women who reported no intravaginal cleansing use or
intravaginal cleansing with water alone (reference) using logistic regression. (C) A comparison of analyte
concentration85% between samples from women who reported intravaginal insertion and women who
reported no intravaginal insertion (reference) using linear regression. (D) A comparison of analyte
concentration <85% between samples from women who reported intravaginal insertion and women who
reported no intravaginal insertion (reference) using logistic regression.
doi:10.1371/journal.pone.0143109.g005
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Fig 6. Clinical cervical ectopy (n = 67). Bolded analytes represent associations with a p-value0.05. A
comparison of analyte concentration between samples among women with cervical ectopy and women
without ectopy (reference). (A) Analytes with >85% detection using linear regression; (B) Analytes with <85%
detection using logistic regression.
doi:10.1371/journal.pone.0143109.g006
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Fig 7. Colposcopy examination (n = 67). Bolded analytes represent associations with a p-value0.05. A
comparison of analyte concentration between samples among women with colposocopic findings and
women without colposcopic findings (reference). (A) Analytes with >85% detection using linear regression;
(B) Analytes with <85% detection using logistic regression. Footnote: 1. The x-axis range is from -15.0 to
+10.0 which is wider than for all other figures.
doi:10.1371/journal.pone.0143109.g007
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Fig 8. Vaginal pH (n = 361). Bolded analytes represent associations with a p-value0.05. Vaginal pH was
measured with test strips during the clinical examination: 3.6–4.1 (normal pH); 4.4–4.7 (high normal pH); and
5.0 and above (abnormal pH). (A) For analytes with >85% detection using linear regression, linear trend for
change in log concentration. (B) Analytes with <85% detection using logistic regression, change in odds of
analyte detection with one unit increase in exposure category.
doi:10.1371/journal.pone.0143109.g008
Immune Activation in the Female Genital Tract
PLOS ONE | DOI:10.1371/journal.pone.0143109 January 27, 2016 20 / 28
Fig 9. White blood cells (WBCs; neutrophils, n = 361; lymphocytes, n = 361).WBCs from the CVL cell
pellet were identified and enumerated. For the statistical analysis, lymphocytes were either present or absent,
and neutrophil were categorized as follows: no cells, 1–10 cells, 11–50 cells, >50 cells. Bolded analytes
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Consistent with our results, Kyongo and colleagues also found a strong correlation between
cervical ectopy and IL-6 and G-CSF, but also IL-1β, IL-8, MIP-1β among Belgian and sub-
Saharan African women [21,22]. Additionally, Hwang and colleagues found that CVL samples
among women with ectopy had high levels of IL-1β, IL-6 and IL-8, but also IL-1α, MIP-1α,
RANTES, TNF-α, IL-10, IL-12 and IFN-γ [54]. There is evidence from published studies that
ectopy is associated with COCs, but not with DMPA [55]. In our study, the signatures for
COCs and ectopy are similar, and it may be that most of the differential expression seen
among women with ectopy could be explained by increased levels of hormones (i.e.
oestrogens).
Vaginal practices are very common in sub-Saharan Africa [56], and have been implicated in
HIV acquisition and associated changes in vaginal microbiota [57]. In this population, intrava-
ginal cleansing is highly prevalent, with many women using soap, while fewer women reported
using cloth for cleansing or inserting substances [58]. Kyongo and colleagues report an increase
in IL-6 and MIP-1 among women reporting using substances other than water for IVP in
South Africa [22]. Our study showed no differential expression of analytes for intravaginal
cleansing with soap; however, most analytes were decreased during visits with reported inser-
tion use, and detergent was the most common substance inserted in our study. In previous in
vitro studies, Nonoxynol-9 (N9), a surfactant (i.e. a detergent), has been shown to cause IL-1
release and activation of NF-kB in cervical and vaginal epithelial cells [8]. Our results suggest
that soaps and detergents may not have a similar effect on the vaginal milieu as N9, though
results should be interpreted with caution. In contrast, cloth use showed increased expression
of the innate and adaptive, inflammatory and anti-inflammatory analytes, signalling an overall
heightened inflammatory state among women using cloth. The mechanism behind this
immune activation may be microabrasions caused by cloth use or introduction of bacteria.
These results are consistent with epidemiological findings from a large individual person data
analysis that showed an association between cloth use and HIV acquisition (pooled adjusted
hazard ratio of 1.47, 95% confidence interval 1.18–1.83) indicating that cloth use may increase
susceptibility to HIV acquisition [57]. More research is needed to understand the inflammatory
effects of well-defined, prevalent IVP.
This study has a number of important strengths. We measured 45 different analytes, and
reported concentrations found in CVLs in realistic trial conditions. We presented unadjusted
raw data to show the differential expression of these analytes associated with biomedical and
behavioural factors that are likely to be present during a clinical trial (e.g. hormonal contracep-
tion use, menstrual cycle stage, seminal plasma exposure). We have presented the data with fig-
ures showing unadjusted point estimates with confidence intervals in order to show signatures
by factors. However, caution is needed when interpreting any one analyte estimate as this
study has multiple comparisons using repeated significance testing which will lead to Type 1
errors or false positives. Therefore, it is more useful to look at the overall signatures, the pat-
terns in types of analytes (e.g. inflammatory cytokines, immunoglobulins), and the strength of
associations.
represent associations with a p-value0.05. (A) For analytes with >85% detection using linear regression,
linear trend for change in log concentration in neutrophils. (B) Analytes with <85% detection using logistic
regression, change in odds of analyte detection with one unit increase in neutrophil category. (C) A
comparison of analyte concentration >85% between samples with presence of lymphocytes and samples
with absent lymphocytes (reference) using linear regression. (D) A comparison of analyte concentration
>85% between samples with presence of lymphocytes and samples with absent lymphocytes (reference)
using logistic regression.
doi:10.1371/journal.pone.0143109.g009
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Fig 10. Haemoglobin (n = 369).Haemoglobin was measured by Hemostix test strips in the CVLs, categories
were none, low (25 erythrocytes [ery]/μL), moderate (80 ery/μL), high (200 ery/μL). Bolded analytes represent
associations with a p-value0.05. (A) For analytes with >85% detection using linear regression, linear trend
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This study also has some limitations. Several biomedical and behavioural factors (e.g. men-
strual phase, COCs, DMPA, rarer types of vaginal practices) had lower statistical power to
detect associations and wide confidence intervals; therefore, caution is warranted in interpret-
ing these results. However, even with lower power, signatures show marked immune activation
for hormonal contraception and vaginal practices with cloth, and relatively less with menstrual
cycle, intravaginal insertion, ectopy and colposcopic findings. Secondly, our methods for
assigning menstrual phase did not identify the exact visit during ovulation, and samples were
not collected during menstruation; therefore differential expression of analytes occurring dur-
ing ovulation or menses only would have been missed. Lastly, we defined healthy visits by the
absence of STIs measured in this study, and there may be unmeasured effects of other STIs
(e.g. Human papillomavirus). Additionally, there may be unmeasured effects of persistent
immune activation after clearance of HSV shedding [59].
Conclusions
Soluble immune proteins may be useful biomarkers to assess immune activation to predict
harm or indicate the risk for HIV-1 acquisition in clinical trials for vaginal microbicides, muco-
sal vaccines and other interventions. Biomedical and behavioural factors such as hormonal
changes, by menstrual cycle stage or hormonal contraception use, recent sex, vaginal practices,
and blood contamination may affect concentration of these proteins. Although, randomization
should ensure that the timing of visits and presence or these factors are similar between trial
arms, investigators should be aware of background variability and collect reliable data on these
factors. Additionally, understanding the modulation of total antibody expression over a men-
strual cycle should inform the assessment of specific antibody responses following a trial of a
candidate HIV vaccine, and provide evidence for the standardization of obtaining samples dur-
ing the menstrual cycle phase.
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